样式: 排序: IF: - GO 导出 标记为已读
-
Residual effects of medications for sleep disorders on driving performance: A systematic review and network meta-analysis of randomized controlled trials Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-23 Michele Fornaro, Claudio Caiazza, Flavia Rossano, Flavia Cilmi, Michele De Prisco, Eduard Vieta, Trevor Thompson, Marco Solmi, Andre Ferrer Carvalho, Felice Iasevoli, Andrea de Bartolomeis
Sleep medications often carry residual effects potentially affecting driving safety, warranting network meta-analysis (NMA). PubMed/EMBASE/TRID/Clinicaltrials.gov/WHO-ICTRP/WebOfScience were inquired for randomized controlled trials of hypnotic driving studies in persons with insomnia and healthy subjects up to 05/28/2023, considering the vehicle's standard deviation of lateral position - SDLP (Standardized
-
Regional differences in mortality risk and in attenuating or aggravating factors in schizophrenia: A systematic review and meta-analysis Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-17 Marco Solmi, Giovanni Croatto, Michele Fornaro, Lynne Kolton Schneider, S. Christy Rohani-Montez, Leanne Fairley, Nathalie Smith, István Bitter, Philip Gorwood, Heidi Taipale, Jari Tiihonen, Samuele Cortese, Elena Dragioti, Ebba Du Rietz, Rene Ernst Nielsen, Joseph Firth, Paolo Fusar-Poli, Catharina Hartman, Richard I G Holt, Anne Høye, Ai Koyanagi, Henrik Larsson, Kelli Lehto, Peter Lindgren, Mirko
People with schizophrenia die prematurely, yet regional differences are unclear.
-
Does valerian work for insomnia? An umbrella review of the evidence Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-14 Valéria Valente, Daniela Machado, Susana Jorge, Christopher L. Drake, Daniel Ruivo Marques
Valerian is one of the most used herbal agents (phytotherapeutics) to manage sleep disturbances, in particular, sleep-onset difficulties in young adults. However, the evidence based on primary studies and systematic reviews that supports its use in this domain is weak or inconclusive. In the current study, an umbrella review was performed on the efficacy of valerian for sleep disturbances with a focus
-
Current level of evidence for improvement of antidepressant efficacy and tolerability by pharmacogenomic-guided treatment: A Systematic review and meta-analysis of randomized controlled clinical trials Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-09 Filip Milosavljević, Prof. Espen Molden, Prof. Magnus Ingelman-Sundberg, Assoc. Prof. Marin M Jukić
The aim of the study was to assess the clinical utility of currently available pharmacogenomic (PGx) tools compared with treatment as usual (TAU), using a meta-analysis of dichotomous and continuous antidepressant efficacy and tolerability data from previously published clinical trials. MEDLINE, clinicaltrial.gov, EU Clinical Trials Register, WHO ICTRP and CENTRAL were systematically searched; of the
-
Suicidal behavior: Not just an epiphenomenon of psychiatric illness Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-07 Maria A. Oquendo, Enrique Baca-Garcia
-
Polygenic risk scores mediating functioning outcomes through cognitive and clinical features in youth at family risk and controls Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-06 Alex G Segura, Elena de la Serna, Gisela Sugranyes, Inmaculada Baeza, Isabel Valli, Irene Martínez-Serrano, Covadonga M Díaz-Caneja, Álvaro Andreu-Bernabeu, Dolores M Moreno, Patricia Gassó, Natalia Rodríguez, Albert Martínez-Pinteño, Llucia Prohens, Carla Torrent, Clemente García-Rizo, Sergi Mas, Josefina Castro-Fornieles
Schizophrenia and bipolar disorder exhibit substantial clinical overlap, particularly in individuals at familial high risk, who frequently present sub-threshold symptoms before the onset of illness. Severe mental disorders are highly polygenic traits, but their impact on the stages preceding the manifestation of mental disorders remains relatively unexplored. Our study aimed to examine the influence
-
What is really different about older age bipolar disorder? Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-06 Annemiek Dols, Martha Sajatovic
-
Social cognition in maltreated individuals: Do type and timing of maltreatment matter? Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-06 Natalia E. Fares-Otero, Inga Schalinski
-
Impact of genetic, sociodemographic, and clinical features on antidepressant treatment trajectories in the perinatal period Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-06 Xiaoqin Liu, Nhung TH Trinh, Naomi R. Wray, Angela Lupattelli, Clara Albiñana, Esben Agerbo, Bjarni J. Vilhjálmsson, Veerle Bergink, Trine Munk-Olsen
Pregnant women on antidepressants must balance potential fetal harm with the relapse risk. While various clinical and sociodemographic factors are known to influence treatment decisions, the impact of genetic factors remains unexplored. We conducted a cohort study among 2,316 women with diagnosed affective disorders who had redeemed antidepressant prescriptions six months before pregnancy, identified
-
Clinical and electrophysiological correlates of hopelessness in the context of suicide risk✰ Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-03 Elizabeth D. Ballard, Roshni P. Nischal, Courtney R. Burton, Deanna K. Greenstein, Grace E. Anderson, Laura R. Waldman, Carlos A. Zarate, Jessica R. Gilbert
Hopelessness is a key risk factor for suicide. This analysis explored whether hopelessness indicates a recent suicide crisis state and is linked with magnetoencephalography (MEG) oscillatory power and effective connectivity differences. Change in hopelessness ratings and effective connectivity post-ketamine were also evaluated in a subsample of high-risk individuals to evaluate correlates of dynamic
-
Rare variants in pharmacogenes influence clozapine metabolism in individuals with schizophrenia Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-03 Djenifer B. Kappel, Elliott Rees, Eilidh Fenner, Adrian King, John Jansen, Marinka Helthuis, Michael J. Owen, Michael C. O'Donovan, James T.R. Walters, Antonio F. Pardiñas
Clozapine is the only licensed medication for treatment-resistant schizophrenia (TRS). Few predictors for variation in response to clozapine have been identified, but clozapine metabolism is known to influence therapeutic response and adverse side effects. Here, we expand on genome-wide studies of clozapine metabolism, previously focused on common genetic variation, by analysing whole-exome sequencing
-
Choosing lithium in the perinatal period Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-03 Alba Roca-Lecumberri, Eva Solé
-
Advancing psychiatric care: The transition from symptom-based diagnosis to personalized psychiatry Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-03 Carlos Lopez-Jaramillo
-
Can cognition screening in the clinic aid personalised treatment in bipolar disorder? Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-03 Kamilla Woznica Miskowiak, Hanne Lie Kjærstad
-
Using digital phenotyping to classify bipolar disorder and unipolar disorder – exploratory findings using machine learning models Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-03 Maria Faurholt-Jepsen, Darius Adam Rohani, Jonas Busk, Morten Lindberg Tønning, Mads Frost, Jakob Eyvind Bardram, Lars Vedel Kessing
The aims were to investigate 1) differences in smartphone-based data on phone usage between bipolar disorder (BD) and unipolar disorder (UD) and 2) by using machine learning models, the sensitivity, specificity, and AUC of the smartphone data in classifying BD and UD. Daily smartphone-based self-assessments of mood and same-time passively collected smartphone data on smartphone usage was available
-
Pharmacodynamic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-03 Konstantinos N. Fountoulakis, Mauricio Tohen, Carlos A. Zarate
The treatment of bipolar depression is one of the most challenging needs in contemporary psychiatry. Currently, only quetiapine, olanzapine-fluoxetine combination, lurasidone, cariprazine, and recently lumateperone have been FDA-approved to treat this condition. The neurobiology of bipolar depression and the possible mechanistic targets of bipolar antidepressant therapy remain elusive. The current
-
Should lithium be used in children and adolescents with bipolar disorder? Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-03 Gonzalo Salazar de Pablo, Allan H. Young
Abstract not available
-
-
-
-
Whole-brain structural and functional neuroimaging of individuals who attempted suicide and people who did not: A systematic review and exploratory coordinate-based meta-analysis Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-01-18 Nicola Meda, Alessandro Miola, Giulia Cattarinussi, Fabio Sambataro
Suicide is the cause of death of approximately 800,000 people a year. Despite the relevance of this behaviour, risk assessment tools rely on clinician experience and subjective ratings.
-
-
-
-
Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-12-22 Marcelo Falchi-Carvalho, Isabel Wießner, Sérgio Ruschi B. Silva, Lucas O. Maia, Handersson Barros, Sophie Laborde, Flávia Arichelle, Sam Tullman, Natan Silva-Costa, Aline Assunção, Raissa Almeida, Érica J. Pantrigo, Raynara Bolcont, José Victor Costa-Macedo, Emerson Arcoverde, Nicole Galvão-Coelho, Draulio B. Araujo, Fernanda Palhano-Fontes
Psychedelics are being increasingly examined for their therapeutic potential in mood disorders. While the acute effects of ayahuasca, psilocybin, and lysergic acid diethylamide (LSD) last over several hours, inhaled N,N-Dimethyltryptamine (DMT) effects last around 10 min, which might provide a cost- and time-effective alternative to the clinical application of oral psychedelics. We aimed at investigating
-
Teratogenicity of valproate: Further reasons for action Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-12-21 Gerard Anmella, Eduard Vieta
Abstract not available
-
Clinical features in co-occuring obsessive-compulsive disorder and bipolar disorder: A systematic review and meta-analysis Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-12-20 Michele De Prisco, Cristiana Tapoi, Vincenzo Oliva, Chiara Possidente, Robertas Strumila, Christine Takami Lageborn, Lorenzo Bracco, Nicolaja Girone, Monica Macellaro, Eduard Vieta, Giovanna Fico
Obsessive-compulsive disorder (OCD) frequently co-occurs with various psychiatric conditions and may impact as many as one-fifth of individuals diagnosed with bipolar disorder (BD). Despite the expanding body of literature on the coexistence of OCD and BD, there is a notable lack of comprehensive data pertaining to the distinct features of obsessive-compulsive symptoms that define this comorbidity
-
The complex scenario behind the term antipsychotic drug Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-12-20 Marco A. Riva, Annamaria Cattaneo
Abstract not available
-
Duration of the psychosis prodrome and its relationship to duration of untreated psychosis across all 12 DSM-IV psychotic diagnoses: Evidence for a trans-diagnostic process associated with resilience Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-12-20 Nnamdi Nkire, Anthony Kinsella, Vincent Russell, John L. Waddington
While duration of the psychosis prodrome (DPP) attracts attention in relation to the developmental trajectory of psychotic illness and service models, fundamental issues endure in the context of dimensional-spectrum models of psychosis. Among 205 epidemiologically representative subjects in the Cavan-Monaghan First Episode Psychosis Study, DPP was systematically quantified and compared, for the first
-
Can antipsychotics prevent transition to psychosis in high-risk population? Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-12-14 Pavel Mohr
Abstract not available
-
Cognitive impairment after recovery from COVID-19: Frequency, profile, and relationships with clinical and laboratory indices Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-12-07 Silvana Galderisi, Andrea Perrottelli, Luigi Giuliani, Maria Antonietta Pisaturo, Palmiero Monteleone, Pasquale Pagliano, Antonio Vita, Maria Lorenza Muiesan, Mario Amore, Matteo Bassetti, Alberto Siracusano, Armida Mucci, Paola Bucci, Giammarco Cascino, Stefano Barlati, Andrea Amerio, Giorgio Di Lorenzo, Cinzia Niolu, Nicola Coppola, Mario Maj
Cognitive impairment (CI) is regarded as a remarkable burden in COVID-19 survivors. Its prevalence and profile, and relationships with the disease clinical and laboratory indices, remain unclear. The present study investigated, in a large sample of patients recovered from COVID-19, the frequency of CI with both a face-to-face screening tool and comprehensive test battery (MCCB). The study also evaluated
-
The never-ending problem: Sample size matters Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-12-05 Michele De Prisco, Eduard Vieta
Abstract not available
-
Investigation of TRPV1 gene expression in bipolar disorder and its association with CB1 and MOR gene expression Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-12-06 Andrea Escelsior, Martino Belvederi Murri, Bruno Sterlini, Samuele Tardito, Tiziana Altosole, Anna Bovio, Beatriz Pereira da Silva, Daniela Fenoglio, Gilberto Filaci, Mario Amore, Gianluca Serafini
Abstract not available
-
A posterior-alpha ageing network is differentially associated with antidepressant effects of venlafaxine and rTMS Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-11-24 Hannah Meijs, Helena Voetterl, Alexander T. Sack, Hanneke van Dijk, Bieke De Wilde, Jan Van Hecke, Peter Niemegeers, Evian Gordon, Jurjen J. Luykx, Martijn Arns
Major depressive disorder (MDD) is a highly prevalent psychiatric disorder, but chances for remission largely decrease with each failed treatment attempt. It is therefore desirable to assign a given patient to the most promising individual treatment option as early as possible. We used a polygenic score (PGS) informed electroencephalography (EEG) data-driven approach to identify potential predictors
-
The significance of an integrated multi-omics approach in psychiatric disorders: A pharmacological perspective. Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-11-15 Mojtaba Oraki Kohshour,Urs Heilbronner
-
Substance P, NPY, CCK and their receptors in five brain regions in major depressive disorder with transcriptomic analysis of locus coeruleus neurons. Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-11-04 Swapnali Barde,Julio Aguila,Wen Zhong,Anna Solarz,Irene Mei,Josee Prud'homme,Miklos Palkovits,Gustavo Turecki,Jan Mulder,Mathias Uhlén,Corina Nagy,Naguib Mechawar,Eva Hedlund,Tomas Hökfelt
Major depressive disorder (MDD) is a serious disease and a burden to patients, families and society. Rodent experiments and human studies suggest that several neuropeptide systems are involved in mood regulation. The aim of this study is two-fold: (i) to monitor, with qPCR, transcript levels of the substance P/tachykinin (TAC), NPY and CCK systems in bulk samples from control and suicide subjects,
-
Infection-associated chronic disability: A transdiagnostic and translational opportunity for neuroscience Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-10-19 Livia J. De Picker, Michael Berk
Abstract not available
-
Do epidemiologists choose the right tools to explore the impact of mental disorders over time? Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-10-19 Mette Lise Lousdal, Oleguer Plana-Ripoll
Abstract not available
-
Methodological concerns in psychedelic research: The issues of nonequivalent psychological support and generalizability. Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-10-19 Richard J Zeifman,Lucas O Maia
-
Digital behavioural signatures reveal trans-diagnostic clusters of Schizophrenia and Alzheimer's disease patients. Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-10-19 Martien J H Kas,Niels Jongs,Maarten Mennes,Brenda W J H Penninx,Celso Arango,Nic van der Wee,Inge Winter-van Rossum,Jose Luis Ayuso-Mateos,Amy C Bilderbeck,Philippe l'Hostis,Christian F Beckmann,Gerard R Dawson,Bernd Sommer,Hugh M Marston
The current neuropsychiatric nosological categories underlie pragmatic treatment choice, regulation and clinical research but does not encompass biological rationale. However, subgroups of patients suffering from schizophrenia or Alzheimer's disease have more in common than the neuropsychiatric nature of their condition, such as the expression of social dysfunction. The PRISM project presents here
-
Unlocking the enigma: Metabolic risks of typical antipsychotics and their link to COVID-19 mortality. Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-10-19 Chia Siang Kow,Dinesh Sangarran Ramachandram,Syed Shahzad Hasan
-
Pharmacological anti-inflammatory treatment in children and adolescents with depressive symptoms: A systematic-review and meta-analysis. Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-10-19 Jasper Vöckel,Anna Markser,Lisa Wege,Heidrun Lioba Wunram,Christine Sigrist,Julian Koenig
Growing evidence suggests an association between inflammatory processes and depressive disorders (DD). DD typically emerge during adolescence. Treatment effects of agents with anti-inflammatory properties in youth DD have not been systematically reviewed. Here, the existing evidence on the use of anti-inflammatory drugs (including polyunsaturated fatty acids, nonsteroidal anti-inflammatory drugs, cytokine
-
Lamotrigine efficacy, safety, and tolerability for women of childbearing age with bipolar I disorder: Meta-analysis from four randomized, placebo-controlled maintenance studies Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-09-27 Eduard Vieta, Sanman Ghorpade, Arunangshu Biswas, Angshuman Sarkar, Abhay Phansalkar, James Cooper
This meta-analysis investigated the efficacy, safety, and tolerability of lamotrigine versus placebo in preventing relapse and recurrence of mood episodes in women of childbearing age with bipolar I disorder. Following up to 16 weeks’ open-label lamotrigine treatment, responders were randomized to double-blind treatment, including lamotrigine 100–400 mg/day or placebo, in four trials of up to 76 weeks
-
Acute effects of mifepristone on emotional processing related brain activity: A functional MRI study Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-09-23 Nefize Yalin, Matthew J. Kempton, Ndaba Mazibuko, Mitul A. Mehta, Allan H. Young, Paul R.A. Stokes
The Hypothalamic-pituitary-adrenal (HPA) axis plays an important role in the pathophysiology of mood disorders, and preliminary data suggests that glucocorticoid receptor (GR) antagonism may be an important therapeutic mechanism. The effects of modulating HPA axis function on emotional processing related brain activity, which may be abnormal in depressed mood, is poorly understood. This study used
-
Sucrose preference test: A systematic review of protocols for the assessment of anhedonia in rodents Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-09-21 Maria João Primo, Diana Fonseca-Rodrigues, Armando Almeida, Pedro M. Teixeira, Filipa Pinto-Ribeiro
Anhedonia is described as a decreased ability to experience rewarding and enjoyable activities, a core symptom of major depressive disorder. The sucrose preference test (SPT) is a widely used and reliable behavioural test to assess anhedonia in rodents, based on a two-bottle choice paradigm. To date, different protocols are in use, inducing variability between researchers and hampering comparisons
-
Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment and self-reported side effects in the euthymic phase of bipolar disorders: Results from the FACE-BD cohort Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-09-21 N. Vidal, E. Brunet-Gouet, S. Frileux, B. Aouizerate, V. Aubin, R. Belzeaux, P. Courtet, T. D'Amato, C. Dubertret, B. Etain, E. Haffen, D. Januel, M. Leboyer, A. Lefrere, P.M. Llorca, E. Marlinge, E. Olié, M. Polosan, R. Schwan, M. Walter, P. Roux
Bipolar disorders (BD) are characterized by cognitive impairment during the euthymic phase, to which treatments can contribute. The anticholinergic properties of medications, i.e., the ability of a treatment to inhibit cholinergic receptors, are associated with cognitive impairment in elderly patients and people with schizophrenia but this association has not been well characterized in individuals
-
Awareness of cardiac autonomic dysregulation by antidepressants Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-09-19 Brenda WJH Penninx
Abstract not available
-
Psychomotor slowing in schizophrenia is associated with cortical thinning of primary motor cortex: A three cohort structural magnetic resonance imaging study Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-09-15 Stefan Fritze, Geva A. Brandt, Anastasia Benedyk, Alexander Moldavski, Lena S. Geiger-Primo, Jamila Andoh, Sebastian Volkmer, Urs Braun, Katharina M. Kubera, Robert C. Wolf, Christoph von der Goltz, Emanuel Schwarz, Andreas Meyer-Lindenberg, Heike Tost, Dusan Hirjak
Psychomotor slowing (PS) is characterized by slowed movements and lower activity levels. PS is frequently observed in schizophrenia (SZ) and distressing because it impairs performance of everyday tasks and social activities. Studying brain topography contributing to PS in SZ can help to understand the underlying neurobiological mechanisms as well as help to develop more effective treatments that specifically
-
Association of polygenic risk for bipolar disorder with resting-state network functional connectivity in youth with and without bipolar disorder Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-09-15 Xinyue Jiang, Clement C. Zai, Alysha A. Sultan, Mikaela K. Dimick, Yuliya S. Nikolova, Daniel Felsky, L. Trevor Young, Bradley J. MacIntosh, Benjamin I. Goldstein
Little is known regarding the polygenic underpinnings of anomalous resting-state functional connectivity (rsFC) in youth bipolar disorder (BD). The current study examined the association of polygenic risk for BD (BD-PRS) with whole-brain rsFC at the large-scale network level in youth with and without BD. 99 youth of European ancestry (56 BD, 43 healthy controls [HC]), ages 13–20 years, completed resting-state
-
Is it stress or is it the hormones? Perinatal depression in fathers Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-09-11 Natalia Chechko, Sarah Kittel-Schneider
Abstract not available
-
Exploring the potential of Esketamine in the treatment of bipolar depression Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-09-04 Bernardo Dell'Osso, Giovanni Martinotti
Abstract not available
-
A central serotonin regulating gene polymorphism (TPH2) determines vulnerability to acute tryptophan depletion-induced anxiety and ventromedial prefrontal threat reactivity in healthy young men Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-09-04 Congcong Liu, Keshuang Li, Meina Fu, Yingying Zhang, Cornelia Sindermann, Christian Montag, Xiaoxiao Zheng, Hongxing Zhang, Shuxia Yao, Zheng Wang, Bo Zhou, Keith M. Kendrick, Benjamin Becker
Serotonin (5-HT) has long been implicated in adaptive emotion regulation as well as the development and treatment of emotional dysregulations in mental disorders. Accumulating evidence suggests a genetic vulnerability may render some individuals at a greater risk for the detrimental effects of transient variations in 5-HT signaling. The present study aimed to investigate whether individual variations
-
Controversies about ADHD: Early or also late-onset? Neurodevelopmental or also stress-related? Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-09-01 Jan Buitelaar
Abstract not available
-
Social cognition and psychosocial functioning in schizophrenia and bipolar disorder: Theory of mind as a key to understand schizophrenia dysfunction Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-09-01 Sarah Corrêa de Sales, Marieli Philippsen, Letícia Stephane de Jesus, Marcelo Alves Carriello, Pedro Henrique Pereira Alvim, Diogo Fernando Bornancin Costa, Laura Canani da Rosa, Mathias Hasse-Sousa, Letícia Sanguinetti Czepielewski, Raffael Massuda
Functional impairment is a common symptom in schizophrenia (SZ) and bipolar disorder (BD). Pharmacological treatments have limited functional recovery in both disorders. Social cognition, a cognitive process, has been associated with functioning in mental disorders. Theory of mind (ToM) is considered a key factor in understanding the social cognitive deficits in SZ and BD. Our study aimed to investigate
-
The prevalence and correlates of suicidal ideation in Chinese psychiatric patients during the fifth wave of COVID-19 in Hong Kong Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-09-01 Heidi Ka Ying Lo, Joe Kwun Nam Chan, Esther Wing Chi Yip, Eileena Mo Ching Chui, Vivian Shi Cheng Fung, Corine Sau Man Wong, Ryan Sai Ting Chu, Yuen Kiu So, Jacob Man Tik Chan, Albert Kar Kin Chung, Krystal Chi Kei Lee, Calvin Pak Wing Cheng, Chi Wing Law, Wai Chi Chan, Wing Chung Chang
People with mental disorders have increased risk of psychological distress during COVID-19. However, there is limited research comprehensively examining factors associated with suicidal ideation, the strongest predictor of suicidal behavior, among psychiatric patients amidst pandemic. We investigated prevalence and correlates of suicidal ideation in 407 Chinese psychiatric outpatients (diagnosed with
-
The polygenic basis of relapse after a first episode of schizophrenia. Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-08-19 Àlex-González Segura,Llucia Prohens,Patricia Gassó,Natalia Rodríguez,Clemente Garcia-Rizo,Lucía Moreno-Izco,Álvaro Andreu-Bernabeu,Iñaki Zorrilla,Anna Mane,Roberto Rodriguez-Jimenez,Alexandra Roldán,Salvador Sarró,Ángela Ibáñez,Judith Usall,Pilar A Sáiz,Manuel J Cuesta,Mara Parellada,Ana González-Pinto,Ester Berrocoso,Miquel Bernardo,Sergi Mas,Gisela Mezquida,Néstor Arbelo,Mario De Matteis,Joaquín
Little is known about genetic predisposition to relapse. Previous studies have linked cognitive and psychopathological (mainly schizophrenia and bipolar disorder) polygenic risk scores (PRS) with clinical manifestations of the disease. This study aims to explore the potential role of PRS from major mental disorders and cognition on schizophrenia relapse. 114 patients recruited in the 2EPs Project were
-
Biological markers of sex-based differences in major depressive disorder and in antidepressant response Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-08-16 Rosana Carvalho Silva, Claudia Pisanu, Elisabetta Maffioletti, Valentina Menesello, Marco Bortolomasi, , Massimo Gennarelli, Bernhard T Baune, Alessio Squassina, Alessandra Minelli
Major depressive disorder (MDD) presents different clinical features in women and men, with women being more affected and responding differently to antidepressant treatment. Specific molecular mechanisms underlying these differences are not well studied and this narrative review aims at providing an overview of the neurobiological features underlying sex-differences in biological systems involved in
-
Effects of cannabis use on antidepressant treatment response to repetitive transcranial magnetic stimulation and ketamine Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-08-13 Mohammad Ali Shenasa, Houtan Totonchi Afshar, Eric A. Miller, Em Ellerman-Tayag, Jyoti Mishra, Dhakshin Ramanathan
Abstract not available
-
Exploring the link between functional connectivity of ventral tegmental area and physical fitness in schizophrenia and healthy controls Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-08-08 Lara Hamzehpour, Tamara Bohn, Lucia Jaspers, Oliver Grimm
Decreased physical fitness and being overweight are highly prevalent in schizophrenia, represent a major risk factor for comorbid cardio-vascular diseases and decrease the life expectancy of the patients. Thus, it is important to understand the underlying mechanisms that link psychopathology and weight gain. We hypothesize that the dopaminergic reward system plays an important role in this. We analyzed
-
Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-08-07 Natacha Perez, Florent Langlest, Luc Mallet, Marco De Pieri, Othman Sentissi, Gabriel Thorens, Federico Seragnoli, Daniele Zullino, Matthias Kirschner, Stefan Kaiser, Marco Solmi, Michel Sabé
Psilocybin is increasingly studied for its antidepressant effect, but its optimal dosage for depression remains unclear. We conducted a systematic review and a dose-response meta-analysis to find the optimal dosage of psilocybin to reduce depression scores. Following our protocol (CRD 42022220190) multiple electronic databases were searched from their inception until February 2023, to identify double-blind